Shenzhen Cell and Gene Therapy Industry CDMO Public Service Platform Officially Launches – Shenzhen Cell Valley Helps Build Full-Chain CGT Ecosystem

On May 9, 2026, at the "Healthcare-Enterprise Collaboration for the Future" Cell and Gene Therapy Collaborative Innovation and Translation Matchmaking Conference, jointly hosted by the Shenzhen Municipal Health Commission, the City's Medical Device and Pharmaceutical Administration Office, and the Party Committee of the City's Medical Device Industry Innovation Chain, the Shenzhen Cell and Gene Therapy Industry CDMO Public Service Platform was officially launched. Xiang Hua, Deputy General Manager of the Cell Valley Group, attended the conference as the group's representative. As one of the four co-founding entities, Shenzhen Cell Valley will take a deep role in the technology translation segment of the platform, helping to build a "Shenzhen Engine" for the city's CGT industry.

The newly launched CDMO Public Service Platform is exclusively operated by Shenzhen Xihe Life Technology Co., Ltd. and jointly established by Weiguang Biologics, Shenye Biotech, Shenzhen Cell Valley, and Saibio Biotechnology. Guided by a development philosophy of "state-owned capital leadership, full-chain empowerment, and global benchmarking," the platform precisely targets three major pain points in the CGT sector: difficulties in scaled production, high commercialization costs, and weak alignment with international standards. It aims to build a one-stop comprehensive CDMO service system compliant with GMP standards of multiple countries, covering the entire process of plasmid DNA, viral vectors, and cell drugs from R&D, manufacturing, and quality control to result translation. With a total investment of 1.6 billion yuan, the platform will be located in the Weiguang Life Science Park in Guangming District, with a planned total area of approximately 40,000 square meters. Once operational, its annual production capacity will reach 60,000 patient doses, fully meeting the scaled production and flexible customization needs of mainstream CGT technology pathways including CAR-T, CAR-NK, and stem cells.

As the core vehicle for technology translation on the platform, Shenzhen Cell Valley, leveraging its technical expertise, result translation experience, and industrial resource advantages in the cell and gene therapy field, will focus on functions such as deploying cutting-edge technologies, bridging clinical outcomes, and incubating innovative projects—unlocking the critical nodes from laboratory research to industrialization. Under the innovative model of "state-owned capital leadership, market-driven operation, and four-party collaboration," Shenzhen Cell Valley will complement the strengths of its partners: it will work with Weiguang Biologics to advance platform operations and management, coordinate with Shenye Biotech to connect industrial capital resources, and cooperate with Saibio Biotechnology to adapt advanced equipment to the relevant scenarios. Together, they aim to build a complete industrial ecosystem loop integrating "construction and operation, capital deployment, technical support, and equipment supply." At the same time, the platform will deeply engage with the clinical needs of top-tier tertiary hospitals, facilitating the industrial implementation of more innovative outcomes in cell and gene therapy.

Looking ahead, Shenzhen Cell Valley will continue to leverage its technological and resource advantages, relying on the CDMO Public Service Platform to support the R&D and production needs of local small and medium-sized CGT enterprises, reduce upfront costs for these companies, and help Shenzhen accelerate its transformation from a hub of CGT technological innovation to a global industrial cluster. In doing so, it will contribute core strength to the high-quality development of the biomanufacturing industry in the Greater Bay Area.